In a groundbreaking advancement within psychiatric medicine, recent research spearheaded by Meijo University scholars has uncovered promising evidence that brexpiprazole, when used alongside existing antipsychotic treatments, may significantly enhance cognitive functions in individuals living with schizophrenia. Notably, the adjunctive use of brexpiprazole demonstrated marked improvements in patients’ information processing speed—one of the most impaired cognitive domains in schizophrenia—without exacerbating psychiatric symptoms. This finding heralds new hope for addressing a core and often treatment-resistant facet of schizophrenia: cognitive dysfunction.
Schizophrenia, a multifaceted psychiatric disorder, presents an intricate clinical picture encompassing positive symptoms such as hallucinations and delusions, as well as negative symptoms including emotional flattening, social withdrawal, and diminished motivation. These clinical manifestations are well-recognized, but cognitive deficits—characterized by reductions in attention, working memory, executive function, and processing speed—remain an equally debilitating yet less treatable dimension. Cognitive impairment affects approximately 75 to 85 percent of schizophrenia patients, profoundly influencing their social integration and ability to function in daily life.
Perhaps most concerningly, cognitive dysfunction directly predicts long-term outcomes more reliably than positive or negative symptoms. Individuals with schizophrenia frequently experience difficulties in sustained attention, rapid information processing, and verbal fluency, impairments that translate into widespread challenges including high unemployment rates and social isolation. To date, therapeutic interventions have predominantly targeted psychotic symptoms, leaving a critical gap in effective cognition-focused treatments.
This gap underscores the importance of the recent observational study led by Professor Hiroyuki Kamei and his team at Meijo University, who evaluated the impact of brexpiprazole (BRX) as an adjunctive agent to standard antipsychotic regimens. Unlike many antipsychotics, BRX exhibits a unique pharmacodynamic profile—it functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors while antagonizing serotonin 5-HT2A and 5-HT7 receptors. Such receptor interactions theoretically support cognitive enhancement, given dopamine and serotonin’s well-documented roles in modulating executive function and processing speed.
The study enrolled nineteen adult outpatients with schizophrenia, all exhibiting significant negative symptom severity as measured by the Positive and Negative Syndrome Scale (PANSS). Over a 16-week period, BRX was added to their existing antipsychotic treatments, which ranged across multi-acting receptor-targeted agents, serotonin-dopamine antagonists, and dopamine partial agonists. Cognitive performance was rigorously assessed using validated instruments including the Trail Making Test (TMT), which gauges information processing speed and cognitive flexibility, and the Word Fluency Test, a measure of executive functioning.
Results revealed that BRX adjunctive therapy elicited significant improvements in TMT Part A scores across all follow-up intervals—4, 8, and 16 weeks—indicating a consistent enhancement in attention and processing speed. These cognitive benefits were notably independent of changes in overall psychiatric symptom severity, suggesting a direct pharmacological effect of BRX on neurocognitive domains rather than secondary gains related to symptom reduction. Other cognitive measures, such as verbal fluency, showed trends toward improvement, though these did not reach statistical significance in this pilot cohort.
These promising outcomes are particularly impactful given the limited sample size and observational nature of the study, which inherently constrains causal inference but nonetheless provides crucial preliminary data. The absence of psychiatric destabilization further emphasizes the safety profile of brexpiprazole when administered as an adjunct, alleviating concerns over potential worsening of psychotic or affective symptoms during cognitive interventions.
Technically, the unique receptor-binding characteristics of BRX may modulate prefrontal cortical circuits critical for cognitive processing. Partial agonism at D2 receptors could enhance dopaminergic signaling in the prefrontal cortex, a brain region notoriously hypoactive in schizophrenia, thereby facilitating improved executive function. Concurrent serotonin receptor antagonism at 5-HT2A and 5-HT7 sites might modulate glutamatergic transmission and neuroplasticity, further supporting cognitive enhancement. Such multi-receptor targeting distinguishes BRX from traditional antipsychotics that mainly exert dopamine antagonism and often neglect cognitive domains.
The implications of these findings extend beyond therapeutic benefits. Cognitive remediation remains a significant unmet need in schizophrenia treatment, directly linked to patients’ quality of life and social recovery. Enhancing cognition pharmacologically could facilitate greater social engagement, occupational functioning, and independence, ultimately reducing the socio-economic burden of schizophrenia. The research team highlights that their work not only addresses cognitive deficits but also aims to expand the clinical role of pharmacists within psychiatric care by integrating cognitive evaluations and adjunctive pharmacotherapy.
Looking forward, larger-scale randomized controlled trials will be essential to validate and extend these findings, enabling clearer mechanistic insights and optimized dosing strategies. Moreover, investigations into long-term cognitive trajectories under brexpiprazole adjunctive therapy will clarify the durability of effects and potential synergistic interactions with psychosocial interventions such as cognitive remediation therapy.
In sum, the Meijo University study positions brexpiprazole as a promising agent to fill a pressing therapeutic void in schizophrenia treatment — the amelioration of cognitive dysfunction without sacrificing psychiatric stability. This advance encapsulates a paradigm shift, emphasizing the necessity of holistic approaches targeting both symptom reduction and cognitive restoration to improve functional outcomes in this complex disorder.
As Professor Kamei asserts, the prospect of integrating BRX into standard regimens marks a significant contribution to psychiatric care, potentially transforming the prognosis for numerous patients who struggle with persistent cognitive deficits. Reinforcing this optimistic outlook, graduate researcher Yuma Shimizu underscores the ongoing commitment to enhancing psychiatric medicine through innovative research and multidisciplinary collaboration.
This pioneering research thus illuminates a new frontier in schizophrenia treatment, underscoring that cognitive improvement is not only attainable but crucial for comprehensive patient recovery and societal reintegration. The scientific and clinical communities eagerly anticipate subsequent studies that will consolidate brexpiprazole’s role within therapeutic frameworks and extend hope to millions affected by this challenging disorder.
Subject of Research: People
Article Title: Improving effects of additional administration of brexpiprazole to antipsychotics on cognitive function in patients with schizophrenia – A pilot study
News Publication Date: 18-Nov-2025
Web References:
https://doi.org/10.1016/j.heliyon.2025.e44179
Image Credits: Ars Electronica from Openverse
Keywords: schizophrenia, cognitive dysfunction, brexpiprazole, antipsychotic adjunctive therapy, information processing speed, partial dopamine agonist, serotonin receptor antagonist, Trail Making Test, cognitive enhancement, psychiatric treatment
